Profluent
CA - EmeryvilleBiotechnology
Focus: Profluent is an AI-driven biotech company specializing in computationally designed proteins for genetic medicine, with a recent $2.25B partnership with Eli Lilly validating its recombinase platform. The company operates at the frontier of AI protein creation across gene therapy, ophthalmology, neurology, and metabolic diseases.
Profile data last refreshed 6h ago · AI intelligence enriched 3w ago
Open Jobs
14-3 this month
Stable — net -3 jobs in 30d
4 added, 7 removed. Backfill posture.
Should You Work at Profluent?
AI assessmentProfluent is a high-upside, early-stage bet for scientists and engineers comfortable with platform risk but energized by partnership validation and frontier AI-protein technology.
Why Work Here
- Landmark $2.25B Eli Lilly partnership (April 2026) signals strong validation and potential for meaningful revenue/valuation inflection, reducing pre-revenue risk.
Data completeness
3/9 — Basic
Company HealthSolid
Pipeline
Early-stage
0 total
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Profluent
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.